Additionally, immune checkpoint inhibitors, including PD-1/PDL-1 and CTLA-4 antibodies, have emerged as the promising therapeutic options for ccRCC patients [20]. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.